ArticleThe Journal of infection2021
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.International journal of clinical practice · 2021Pooled it
- Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients.Immunity, inflammation and disease · 2024Article
- IL1RA mediated the effects of aspirin on COVID-19 severity: A Mendelian randomization study.The Journal of infection · 2023Article
- Fluid restriction management in the treatment of COVID-19: a single-center observational study.Scientific reports · 2022Observational
- Colchicine Against SARS-CoV-2 Infection: What is the Evidence?Rheumatology and therapy · 2022Review
- Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With Coronavirus Disease-19.Frontiers in cardiovascular medicine · 2022Article
- Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine.Journal of clinical medicine · 2021Review
- Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2021Review
- Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.Journal of the neurological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.